CA Patent

CA3087176A1 — Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Assigned to Scynexis Inc · Expires 2019-07-11 · 7y expired

What this patent protects

Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived tr…

USPTO Abstract

Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived triterpenoid antifungal compounds are inhibitors of (1,3)-ß-D-glucan synthesis and are useful in the treatment or prevention of fungal infections, such as systemic fungal infections, including those caused by Candida and Aspergillus species.

Drugs covered by this patent

Patent Metadata

Patent number
CA3087176A1
Jurisdiction
CA
Classification
—
Expires
2019-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Scynexis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.